What is Versavo?

Versavo is a biosimilar bevacizumab and is indicated for the treatment of multiple cancers. It is used in combination with other chemotherapy drugs to treat cervical, colorectal, glioblastoma and non-squamous non-small cell lung cancer.

Storage Conditions

2-8 degrees Celsius (refrigerate),Do not freeze.

Presentation

Vial containing concentrate for solution for infusion.

Route of Administration

Intravenous (IV) (upon prescription only and administered by a healthcare provider.)

Indications

Metastatic Colorectal Cancer (mCRC):

mCRC is a stage of colorectal cancer where it spreads beyond the colon or rectum to other parts of the body, often requiring aggressive treatment for better survival.

How Bevacizumab works?

Mechanism of Action

Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.

We Meet Global Standards

CDSCO
ISO 9001
INVIMA
SAHPRA

Our News, Stories, and Insights

Pharmacokinetics and Pharmacodynamics Results
  • Publication
  • 31-12-2016

Pharmacokinetics and Pharmacodynamics Results of a Double-blind Randomized Parallel Arm Study Comparing 3 Anti CD20 Monoclonal Antibodies in Moderate to Severe Seropositive Rheumatoid Arthritis Inadequately Responding to Methotrexate patients

  • Publication
  • 31-12-2016

Double-blind Randomized Parallel Arm Study of 3 Anti CD20 Monoclonal Antibodies in Patients with Moderate to Severe, Seropositive Rheumatoid Arthritis Inadequately Responding to Methotrexate Based Therapy. Efficacy Safety & Immunogenicity Results

  • Publication
  • 21-06-2016

Population pharmacokinetics of Reditux, a biosimilar Rituximab, in diffuse large B‑cell lymphoma

  • Publication
  • 06-08-2019

Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis